^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
olanzapine
i
Other names: LY-170052, LY 170053
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
DRD2 antagonist, DRD1 antagonist, Serotonin 2A receptor antagonist
Related drugs:
1d
Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy (clinicaltrials.gov)
P3, N=100, Recruiting, Blokhin's Russian Cancer Research Center
New P3 trial
|
olanzapine
14d
DREAMS-Phen: Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach (clinicaltrials.gov)
P2, N=288, Not yet recruiting, University Hospital, Strasbourg, France | Initiation date: Jan 2026 --> Oct 2026
Trial initiation date
|
Clopixol (zuclopenthixol) • olanzapine
21d
Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis (clinicaltrials.gov)
P=N/A, N=2000, Completed, Shandong Cancer Hospital and Institute | Recruiting --> Completed
Trial completion
|
olanzapine
28d
GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer (clinicaltrials.gov)
P2, N=26, Not yet recruiting, University of Illinois at Chicago
New P2 trial
|
olanzapine
1m
Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area (clinicaltrials.gov)
P=N/A, N=100, Not yet recruiting, University of Alabama at Birmingham
New trial • Adverse events
|
olanzapine
1m
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC (clinicaltrials.gov)
P2, N=156, Recruiting, Second Affiliated Hospital of Nanchang University | Not yet recruiting --> Recruiting | Trial completion date: May 2028 --> May 2027 | Trial primary completion date: Dec 2027 --> Dec 2026
Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
Opdivo (nivolumab) • olanzapine
1m
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications (clinicaltrials.gov)
P3, N=380, Recruiting, Minerva Neurosciences
New P3 trial
|
olanzapine
1m
An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC (clinicaltrials.gov)
P4, N=200, Recruiting, Shanghai 6th People's Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
dexamethasone injection • fosaprepitant • olanzapine
2ms
Exploration and mechanism research on the preventive and synergistic therapeutic effects of systematic interpersonal therapy on depressive disorders with mixed characteristics in adolescents (ChiCTR2600121573)
P=N/A, N=411, Peking University Sixth Hospital ( Institute of Mental Health ); Peking University Sixth Hospital ( Institute of Mental Health )
New trial
|
fluoxetine • olanzapine
2ms
Exploratory Clinical Study on the Dexamethasone-Free, Optimized Antiemetic Regimen with NEPA (Netupitant-Palonosetron) Capsules for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately to Highly Emetogenic Chemotherapy（XDF-NEPA） (ChiCTR2600119239)
P=N/A, N=372, Zhongshan Hospital Affiliated to Xiamen University; Zhongshan Hospital Affiliated to Xiamen University
New trial
|
dexamethasone injection • olanzapine
2ms
Phase III Single-Center, Randomized Controlled, Open-Label Clinical Study of Olanzapine 5mg Combined with Standard Triple Antiemetic Regimen in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy Regimens (ChiCTR2600118281)
P3, N=200, Recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
New P3 trial
|
aprepitant oral • dexamethasone injection • olanzapine • ondansetron
2ms
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (clinicaltrials.gov)
P3, N=227, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting | N=360 --> 227
Enrollment closed • Enrollment change
|
megestrol • olanzapine
Share via
